Stage 4 vulvar cancer means the disease has spread beyond the vulva itself, either invading nearby structures like the pelvic bone or producing fixed, ulcerated lymph node metastases, or in the case of stage IVB, reaching distant organs. Five-year survival rates drop sharply at this point, falling to roughly 33% for stage IVA and around 22% for stage IVB in large registry data. Despite those numbers, treatment is not purely palliative for everyone with a stage 4 diagnosis. Advances in chemoradiation, reconstructive surgery, and emerging immunotherapy options have expanded what is possible, though the gains vary considerably depending on a person’s age, overall health, and the molecular profile of the tumor.
What Stage 4 Actually Means
Vulvar cancer staging follows the FIGO system, which was updated in 2021. The staging divides stage 4 into two substages that carry very different implications. In stage IVA, the cancer has either produced fixed or ulcerated lymph node metastases in the groin region, or the primary tumor itself has become fixed to the pelvic bone. In stage IVB, the cancer has spread to distant sites, which most often means distant lymph nodes or organs like the lungs or liver.1International Journal of Gynecological Cancer. Validation of the 2021 FIGO staging schema for advanced vulvar cancer
That distinction matters because IVA disease is still considered locoregionally advanced. The cancer is extensive, but it has not traveled to a distant part of the body. Some IVA patients are candidates for aggressive local treatment with curative intent. IVB patients, by contrast, have distant metastatic disease, and treatment goals shift more toward controlling symptoms and extending life. When someone receives a “stage 4” diagnosis, the first question to clarify with the medical team is which substage they fall into, because the treatment roadmap differs substantially.
Survival Statistics and What Shapes Them
A large German registry study covering thousands of vulvar cancer patients found that the five-year relative survival rate was about 33% for stage IVA and roughly 22% for stage IVB.2PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study Those numbers represent population-level averages, which means they include very elderly patients, people with serious comorbidities, and those who received minimal treatment alongside younger, healthier patients who underwent aggressive multimodal therapy. A smaller Croatian study found even bleaker outcomes, with no stage IV patients surviving beyond 14 months, though that series involved only a handful of stage IV cases and should not be treated as a reliable benchmark.3PubMed Central. Prognostic Factors for Vulvar Cancer
Age is a powerful modifier. In that same German registry, five-year overall survival across all stages was about 89% for women under 55 but dropped to 68% for women over 75.4PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study This partly reflects biology, but it also reflects treatment intensity. Older, frailer patients are less likely to receive the full course of surgery and radiation that younger patients do. A recent geriatric screening study found that women who screened positive for frailty had dramatically lower two-year survival (40% compared to 85%), and one in five of those frail patients did not receive standard adjuvant treatment at all.5SpringerLink. Impact of preoperative geriatric screening and comorbidity assessment in patients with vulvar and vaginal cancer This means that some of the survival gap attributed to advanced stage is actually driven by the age and fitness of the patient population at that stage.
How Molecular Subtype Affects the Outlook
Not all vulvar squamous cell cancers behave the same way, even at the same stage. The two main molecular tracks are HPV-positive tumors and HPV-negative tumors with p53 mutations. Patients with HPV-negative, p53-mutant disease fare considerably worse. One study found they had roughly three and a half times the risk of death and nearly four times the risk of recurrence compared to HPV-positive patients.6Gynecologic Oncology. Prognostic and pathological significance of molecular classification in vulvar squamous cell carcinoma This held even after adjusting for other known risk factors, meaning the molecular subtype carried independent prognostic weight.
From a practical standpoint, knowing the molecular subtype helps oncologists calibrate how aggressive treatment needs to be and, increasingly, which systemic therapies might be worth trying. HPV-positive tumors tend to express certain immune markers that can make them more responsive to immunotherapy. HPV-negative, p53-mutant tumors are biologically more resistant and are the focus of efforts to develop targeted therapies aimed at specific molecular vulnerabilities.
Surgery for Locally Advanced Disease
When stage IVA cancer involves the tumor being fixed to nearby structures but has not spread to distant organs, some centers pursue pelvic exenteration, an extensive operation that removes the tumor along with adjacent organs it has invaded. A Welsh center that took this approach for locally advanced vulvar cancer reported a five-year survival rate of about 67%, with no deaths within 30 days of surgery, though the rate of major complications within that first month was 42%.7PubMed Central. Pelvic Exenteration for the Treatment of Locally Advanced Vulvar Cancer in South West Wales That survival figure is strikingly better than the population averages for stage IV, illustrating how a carefully selected surgical population can outperform registry statistics. The key word is “selected.” These patients were deemed fit enough for a very demanding procedure, and that selection itself creates a favorable bias in the numbers.
However, the trend in recent decades has been away from relying on exenteration as the first option. Chemoradiation, either before surgery to shrink the tumor or as the primary treatment, now allows many patients to preserve organs that would have previously been removed.8International Journal of Gynecological Cancer. Definitive chemoradiation or radiation therapy alone for the management of vulvar cancer This shift has not necessarily improved survival compared to radical surgery, but it has substantially improved quality of life for many patients by avoiding the most disfiguring operations.
Reconstruction After Radical Surgery
When radical vulvectomy is needed, the wound left behind is often large and prone to breakdown. Several reconstructive flap techniques have been developed to close these defects, reduce infection risk, and speed recovery. A study comparing radical vulvectomy alone to vulvectomy with gluteus maximus flap reconstruction found that the flap group had shorter hospital stays (averaging 38 days versus 86 days), fewer wound separations requiring reoperation, and earlier return to walking.9PubMed. Reconstruction of surgical defects using the gluteus maximus myocutaneous flap following radical vulvectomy Other flap options include the anterolateral thigh flap, which uses tissue from the outer thigh, and the rectus abdominis flap from the lower abdomen.10PubMed. Anterolateral thigh vastus lateralis myocutaneous flap for vulvar reconstruction after radical vulvectomy: a preliminary experience11medRxiv. Radical Vulvectomy with Rectus Abdominis Flap Reconstruction for Recurrent Vulvar Cancer Post-Radiotherapy: Clinical Efficacy and Functional Outcomes
The choice of flap depends on the size and location of the defect, whether the patient has had prior radiation (which damages local tissue and makes healing harder), and the surgeon’s expertise. Reconstruction is not purely cosmetic. It reduces the risk of chronic wound problems, shortens recovery time, and makes a meaningful difference to how patients feel about their bodies afterward. For someone facing radical surgery for stage 4 disease, asking about reconstruction options upfront is worth doing, since not all centers offer the full range of techniques.
Managing Bulky Lymph Nodes
Stage IVA often involves bulky, fixed groin lymph nodes. How those nodes are handled is one of the most consequential treatment decisions. The traditional approach has been full inguinofemoral lymph node dissection, surgically removing all the lymph nodes in the groin, followed by radiation. An alternative approach is nodal debulking, where only the visibly enlarged nodes are removed and radiation is relied on to treat any remaining microscopic disease. The rationale is that this reduces surgical morbidity without sacrificing survival.12PubMed. Squamous cell carcinoma of the vulva with bulky positive groin nodes-nodal debulking versus full groin dissection prior to radiation therapy
For some patients with grossly enlarged groin nodes, radiation alone (with or without chemotherapy) has been used as a definitive treatment, delivered at doses in the range of 60 to 70 Gy to the involved nodes.13PubMed. Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy This approach avoids groin surgery entirely and the significant wound complications that come with it, but the dose needed is high and carries its own side effects. The best approach is still debated, and clinical decisions are typically individualized based on how fixed the nodes are, the patient’s surgical fitness, and institutional experience.
Lymphedema as a Treatment Consequence
One of the most burdensome complications of vulvar cancer treatment is lower limb lymphedema, chronic swelling in the legs caused by damage to the lymphatic drainage system during surgery or radiation. A meta-analysis of 27 studies estimated the overall rate at about 29%, though when restricted to better-designed prospective studies, the figure was closer to 17%.14PubMed Central. Incidence of lower limb lymphedema after vulvar cancer A systematic review and meta-analysis The risk was roughly five times higher in women who underwent full inguinofemoral lymph node dissection compared to those who had a less invasive sentinel node biopsy. Other risk factors included wound infection, older age, higher body weight, and radiation therapy.
Combining surgery and radiation to the groin appears to increase the lymphedema risk further, though the data are not entirely clear-cut. One study found rates of clinically significant chronic lymphedema ranged from about 7% with radiation alone to about 11% with surgery alone and 13 to 17% when the two were combined, though the differences did not reach statistical significance in that particular analysis.15International Journal of Gynecological Cancer. The Effect of Groin Treatment Modality and Sequence on Clinically Significant Chronic Lymphedema in Patients With Vulvar Carcinoma For patients with stage 4 disease, who frequently require both surgery and radiation, lymphedema prevention and early management should be part of the treatment plan from the start, not addressed only after symptoms appear.
Immunotherapy and Targeted Therapy
For women whose stage 4 vulvar cancer progresses after surgery and chemoradiation, systemic therapy options have historically been limited. Pembrolizumab, an immune checkpoint inhibitor, has been studied in previously treated advanced vulvar squamous cell carcinoma through the KEYNOTE-158 trial. The overall response rate was about 11%, with a median overall survival of roughly 6 months. Among patients who did respond, the responses tended to be durable, lasting a median of about 20 months.16PubMed. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study Individual case reports have also documented partial responses to pembrolizumab in women with metastatic vulvar cancer who had exhausted other options.17Gynecologic Oncology Reports. Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines
The response rate to immunotherapy is modest for the group as a whole, but the durability in responders is encouraging. The challenge is identifying who will benefit before starting treatment. PD-L1 expression, the biomarker most commonly used to predict immunotherapy response in other cancers, did not clearly predict response here. In the KEYNOTE-158 study, the response rate was actually higher in the small group of PD-L1-negative patients than in PD-L1-positive patients, though the PD-L1-negative group was very small, making firm conclusions risky.18PubMed. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study
Targeted therapies aimed at specific molecular pathways are also being explored. Erlotinib, which targets the epidermal growth factor receptor (EGFR), showed some activity in a small case series where two of five patients achieved stable disease and another two had partial responses.19PubMed Central. Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature Early-phase reports have suggested that EGFR-targeting drugs deserve further study in locally advanced vulvar cancer.20PubMed. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva Looking ahead, researchers have called for trials of antibody-drug conjugates and basket trials incorporating vulvar cancer alongside other perineal squamous cell cancers, along with inhibitors targeting cell cycle and DNA damage response pathways, particularly in HPV-negative tumors.21PubMed Central. Advances in Vulvar Cancer Biology and Management
The Role of PET Scans in Staging
Accurately mapping the extent of stage 4 disease is critical for treatment planning. PET/CT scans, which detect metabolically active cancer tissue throughout the body, are commonly used for this purpose. However, their accuracy for detecting groin lymph node metastases in vulvar cancer is somewhat disappointing. One study found that on a patient-by-patient analysis, the sensitivity of PET/CT for detecting groin node metastases was only 50%, meaning half of patients with positive nodes were missed. The specificity was 67%. The scan performed better on a per-groin basis, with 85% specificity but still just 53% sensitivity.22Wolters Kluwer Health. 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?
Where PET/CT does add clear value is in detecting distant metastases or pelvic node involvement that would change the staging from IVA to IVB, or that would alert the team to disease beyond what was clinically suspected. In that same study, PET/CT picked up pelvic and para-aortic nodal metastases that might otherwise have been missed. So the scan’s usefulness is less about replacing surgical staging of the groin and more about catching unexpected distant spread that would alter the treatment plan entirely.
Quality of Life, Body Image, and Sexual Function
Stage 4 disease and its treatment take a heavy toll that goes well beyond survival statistics. A study of Norwegian vulvar cancer survivors found that 43% reported impaired physical functioning and 30% had impaired emotional, cognitive, or social functioning. Only about 20% of survivors were sexually active, compared to 69% of age-matched women without cancer, and those who were sexually active reported significantly higher levels of sexual dysfunction.23PubMed Central. Long-term quality of life, vulvar symptoms, and sexual functioning: A cross-sectional study of Norwegian vulvar cancer survivors
Treatment-specific symptoms drive much of this burden. Research from an Eastern European center found that vulvar cancer survivors scored their overall quality of life at a reasonable 65 out of 100, but treatment-related symptoms like vulvar scarring, vulvar swelling, and groin and leg lymphedema significantly dragged down daily functioning. Body image perception scored just 34 out of 100, reflecting how profoundly the visible and sensory changes from surgery and radiation affect how women feel about themselves.24PubMed Central. Prognostic Factors and Quality of Life in Vulvar Cancer Patients: 12-Year Results from a Eastern European Center Fatigue, pain, and sleep disturbances persisted long after treatment ended. These findings argue strongly for integrating psychosocial support and rehabilitation into the treatment plan rather than treating them as afterthoughts.
Why Vulvar Cancer Is Often Diagnosed Late
Vulvar cancer is uncommon enough that many women and even some clinicians do not recognize its early symptoms. Persistent itching, a lump or sore that does not heal, skin color changes, or unexplained bleeding are easily mistaken for benign skin conditions or infections. Research into delayed presentation has identified several compounding factors: lack of knowledge about the disease, embarrassment about genital symptoms, financial barriers, transportation difficulties, and limited access to specialized care.25Stellenbosch University. Factors related to the late presentation of women with vulvar cancer
The delay is not only on the patient side. General practitioners may initially treat vulvar symptoms empirically with antifungal or steroid creams for months before considering a biopsy. By the time a specialist sees the patient, the disease may have progressed to an advanced stage. This pattern is one reason why a disproportionate number of vulvar cancer cases are diagnosed at stages III and IV, particularly among older women and those in lower-resource settings.
Non-Squamous Vulvar Cancers at Advanced Stages
While squamous cell carcinoma accounts for the vast majority of vulvar cancers, rare histologies like vulvar Paget’s disease occasionally present at advanced stages. Paget’s disease of the vulva is generally an indolent condition confined to the skin surface, but in roughly 10% of cases it can invade deeper tissues and metastasize to lymph nodes or distant organs. Around 5 to 68% of reported cases have shown some degree of invasive disease, a wide range that reflects small sample sizes and inconsistent reporting across studies. Even so, the overall five-year survival for vulvar Paget’s disease is between 75 and 90%, substantially better than squamous cell carcinoma at the same stage.26PubMed Central. Vulvar Paget’s Disease: A Systematic Review of the MITO Rare Cancer Group Other rare types, including melanoma and Bartholin gland carcinoma, each follow their own staging systems and treatment algorithms and are managed quite differently from squamous disease.
Palliative Interventions for Unresectable Disease
When stage 4 vulvar cancer cannot be surgically removed and has progressed beyond what radiation can control, the focus shifts to managing symptoms and maintaining comfort. One of the more frightening complications of very advanced disease is femoral arterial blowout, where the tumor erodes into a major blood vessel in the groin. Endovascular techniques, which use catheters placed through the blood vessels to block or reroute flow, have been used successfully to manage this life-threatening complication in a minimally invasive way.27PubMed. Multimodal endovascular palliation for femoral arterial blowout in the setting of metastatic vulvar carcinoma Palliative radiation can also help control bleeding, pain, and fungating wounds. For women with IVB disease who are not candidates for systemic therapy, coordinated palliative care that addresses wound management, pain, lymphedema, and emotional support is often the most meaningful intervention their medical team can offer.